1. Home
  2. ELTX vs PSNL Comparison

ELTX vs PSNL Comparison

Compare ELTX & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$2.05

Market Cap

63.3M

Sector

Health Care

ML Signal

HOLD

Logo Personalis Inc.

PSNL

Personalis Inc.

HOLD

Current Price

$16.23

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELTX
PSNL
Founded
2011
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.3M
1.4B
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
ELTX
PSNL
Price
$2.05
$16.23
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$18.00
$12.20
AVG Volume (30 Days)
281.3K
3.5M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
39.29
33.58
EPS
N/A
N/A
Revenue
$2,301,000.00
$69,648,000.00
Revenue This Year
N/A
$15.34
Revenue Next Year
N/A
$41.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.17
$4.96
52 Week High
$16.00
$18.89

Technical Indicators

Market Signals
Indicator
ELTX
PSNL
Relative Strength Index (RSI) 22.25 55.28
Support Level N/A $7.62
Resistance Level $3.32 $16.39
Average True Range (ATR) 0.13 0.77
MACD -0.04 -0.16
Stochastic Oscillator 4.33 12.63

Price Performance

Historical Comparison
ELTX
PSNL

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

About PSNL Personalis Inc.

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Share on Social Networks: